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Abstract
RNA interference (RNAi) of virus-specific genes offers the possibility of developing a new anti-hepatitis B virus (anti-HBV)
therapy. Recent studies have revealed that siRNAs can induce an innate immune response in vitro and in vivo. Here, HBVx
(HBx) mRNA expression and HBV replication were significantly inhibited, followed by the enhancement of expression of
type I interferons (IFNs), IFN-stimulated genes (ISG15 and ISG56) and proinflammatory cytokines after HepG2.2.15 cells were
transfected with chemically synthesized HBx-siRNAs. Transfection with HBx-siRNAs also significantly increased expression of
dsRNA-dependent protein kinase R (PKR) in HepG2.2.15 cells, followed by activation of downstream signaling events such as
eukaryotic initiation factor 2a (eIF2-a). In PKR-over-expressing HepG2.2.15 cells, HBx-siRNAs exerted more potent inhibitory
effects on HBV replication and greater production of type I IFNs. By contrast, the inhibitory effect of HBx-siRNAs on HBV
replication was attenuated when PKR was inhibited or silenced, demonstrating that HBx-siRNAs greatly promoted PKR
activation, leading to the higher production of type I IFN. Therefore, we concluded that PKR is involved in the innate
immune effects mediated by HBx-siRNAs and further contributes to HBV inhibition. The bifunctional siRNAs with both gene
silencing and innate immune activation properties may represent a new potential strategy for treatment of HBV.
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Introduction
HepatitisBvirus(HBV)infectionisanimportantdiseasewith400
million HBV carriersworldwide.HBV infectionmaycausecirrhosis
and hepatocellular carcinoma (HCC) and HBV-induced diseases
cause 1 million deaths annually [1]. Recent studies have shown that
RNA interference (RNAi) is a process whereby double-stranded
RNA (dsRNA) induces a sequence-specific post-transcriptional
silencing of homologous genes. This process is an evolutionarily
conserved surveillance mechanism mediated by small interfering
RNAs (siRNAs) of the length of 21–23 nucleotides. In the natural
RNAi pathway, siRNAs are derived from the processing of long
dsRNAs by the nuclease Dicer into discrete 21-mers [2,3]. A
number of recent studies have demonstrated that chemically
synthesized siRNAs or vector-expressed shRNA targeting HBV
elements inhibit HBV replication [4,5,6,7].
It is noted that intracellular delivery of siRNA could activate
immune system and induce the production of cytokines both in vivo
and in vitro. The response by RNA may be induced by three classes
of viral pattern recognition receptors (PRRs): the Toll-like
receptors (TLRs), the RIG-like helicase (RLH) receptors such as
RIG-I and MDA-5, nucleotide-binding domain (NBD)- and
leucine-rich-region (LRR)-containing family of cytoplasmic pro-
teins (known as NLRs) [8]. RIG-I is the key sensor of negative
strand RNA viruses in the cytosol of cells [9,10], recognizing RNA
with a triphosphate group at the 59-end in a sequence-independent
manner. Some synthetic and natural RNAs (e.g. poly I:C, virus
genomes, virus replication intermediates, viral transcripts, or self-
RNA cleaved by RNase L) also serve as RIG-I agonists
[9,10,11,12,13]. The natural ligand for MDA-5 remains to be
identified, but long poly I:C can serve as an artificial agonist for
this RLH [14]. TLR3 is engaged specifically by dsRNA, which is
present either in viral genomes or generated after viral replication,
and is involved in the induction of type I IFN responses. Indeed, a
group of siRNAs stimulated monocytes or dendritic cells to
produce proinflammatory cytokines and type I IFNs [15,16]. In
addition, some studies have demonstrated that immune recogni-
tion of siRNA is sequence dependent and likely involves signaling
through the endosomal TLR7 pathway [17,18].
The dsRNA-dependent protein kinase R (PKR), acting as a
cytoplasmic RNA sensor, can also recognize molecular patterns in
RNA and thus differentiate self from non-self. During viral infection,
PKR binds viral dsRNA, autophosphorylates and subsequently
phosphorylates the alpha subunit of translation initiation factor 2
(eIF2-a) [19,20]. Several reports reported that siRNAs can activate
PKR signal pathway in a sequence independent manner, particu-
larly when they are combined with lipids, during in vitro cell
transfection [21,22,23]. The mechanisms that enable cells to sense
and respond to dsRNA are not completely understood.
The HBV genome consists of four open reading frames (ORFs)
with overlapping sequences. The HBVx (HBx) gene is essential for
HBV viral infection and plays an important role in the devel-
opment of hepatoma. Here, we designed four pairs of HBx-specific
siRNAs on basis of the conserved region among the x gene and
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27931then examined whether the HBx-siRNAs with a lipid carrier can
trigger immune responses in HepG2.2.15 cells. We then provided
evidence that the non-specific innate immune responses induced
by HBx-siRNAs were mediated by PKR. As type I IFN can be
used for the treatment of virus hepatitis, these observations
prompted us to investigate if the siRNA complex could achieve
both gene silencing and IFN induction in hepatocytes. We finally
demonstrate that the contribution of the immunostimulatory
properties of siRNAs to HBV inhibition revealed in our study
would be helpful for the siRNA-based antiviral therapy.
Materials and Methods
Cell line and cell culture
HepG2.2.15 cells (serotype ayw, genotype D), derived from
HepG2 cells transfected with a plasmid carrying HBV genome
DNA [20], were maintained in complete Dulbecco’s modified
Eagle medium (DMEM; GIBCO/BRL, USA) supplemented with
10% fetal bovine serum (FBS) at 37uC in a humidified atmosphere
containing 5% CO2.
Transfection
The sense and antisense strands of HBx-siRNAs were annealed
and depurated by HPLC (RiboBio, Guangzhou China). HBx-
siRNA sequences are shown in Table 1. HepG2.2.15 cells were
seeded for 12 h, and transfected with Lipofectamine
TM 2000/
siRNA (Invitrogen Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s description. The PKR inhibitor
C16 (Merck Calbiochem, Germany) was dissolved in DMSO
according to the manufacturer’s instructions and was added to
cells at 1 h before exposure to siRNA, with the final concentration
of 2 mM. For IFN Receptor (IFNR) neutralization, anti-IFNR
antibody (PBL Biomedical Laboratories, USA) was added at 12 h
before siRNA transfection [24]. The target sequences of PKR-
siRNA (siPKR) were: GAA CUG CCU AAU UCA GGA C,and
were synthesized by Ribo Company (RiboBio, Guangzhou,
China). The Full-length human PKR expressing vector was
generously provided by Stefan Rothenburg (Laboratory for Host-
Specific Virology, Division of Biology, Kansas State University).
The PKR catalytically inactive vector (cMyc-His-tagged PEF6-
HPKR-K296R) was kindly supplied by BCCM/LMBP (Belgian
Co-ordinated Collections of Micro-Organisms).
Quantitative real-time polymerase chain reaction (PCR)
analysis
Total RNA was prepared from treated HepG2.2.15 cells using
Trizol extraction reagent (Invitrogen, Carlsbad, CA, USA).
Approximately 2 mg of RNA was reverse transcribed using the
M-MLV first-strand cDNA synthesis kit (Promega Corporation,
Madison, WI, USA) and oligo(dT) primer as recommended by the
manufacturer. Quantitative PCR was performed on an iCycleriQ
real-time PCR system (Bio-Rad, USA). Amplified products were
detected using SYBR Green PCR Master Mix (Toyobo Co. Ltd.,
Osaka, Japan). The sequences of primer pairs specific for each
gene are shown in Table 2. The PCR was initially denatured at
95uC for 10 min, followed by 45 PCR cycles of 95uC for 30 s,
60uC for 30 s and 72uC for 30 s. The fold changes in expression
were calculated relative to the expression of GAPDH.
Analysis of HBV DNA
Viral particles in the supernatants were quantified by fluores-
cence real-time polymerase chain reaction (FQ-PCR) according to
the kit’s instructions (Da-An, Guangzhou, China). Briefly, cells
were transfected with siRNA as above. The supernatants were
collected, and mixed with an equal volume of DNA extraction
agent, then mixed violently for 10 s, centrifuged for several
seconds and boiled for 10 min. Then, the supernatants were
collected to test the content of HBV DNA. The primers specific for
the HBV S region were P1: 59-ATCCTGCTGCTATGCCT-
CATCTT-39; P2: 59-ACAGTGGGGGAAAGCCCTACGAA-39.
The fluorescent probe was 59-RTGGCTAGTTTACAGTGC-
CATTTGQ-39, R as report fluorophore and Q as quench
Table 1. Sequences of chemically synthesized HBx-siRNAs.
Name Type Sequence 59R 39
siRNA1-sense RNA GGUCUUACAUAAGAGGACUdTdT
siRNA1-antisense RNA AGTCCTCTTATGTAAGACCdTdT
siRNA2-sense RNA GGACGUCCUUUGUUUACGUdTdT
siRNA2-antisense RNA ACGTAAACAAAGGACGTCCdTdT
siRNA3-sense RNA CCGACCUUGAGGCAUACUUdTdT
siRNA3-antisense RNA AAGUAUGCCUCAAGGUCGGdTdT
siRNA4-sense RNA UGUGCACUUCGCUUCACCUdTdT
siRNA4-antisense RNA AGGTGAAGCGAAGTGCACA dTdT
doi:10.1371/journal.pone.0027931.t001
Table 2. Sequences of primers specific for human genes used
for real-time PCR analysis.
Target
sequence Sequence (59 R 39)
size
(bp)
GAPDH R: GAAGGTGAAGGTCGGAGT
F: CATGGGTGGAATCATATTGGAA
155
IFN-a R: CTC CTT TCT CCT GCC TGA AG
F: AAG TGT CTC ATC CCA AGT AGC
170
IFN-b R: TGCTCTCCTGTTGTGCTTCTCC
F: CATCTCATAGATGGTCAATGCGG
222
ISG15 R: GGACAAATGCGACGAACCTCT
F: CCCTCGAAGGTCAGCCAGA
158
ISG56 R: CTTGAGCCTCCTTGGGTTCG
F: GCTGATATCTGGGTGCCTAAGG
137
iNOS R: GACAAGAGGCTGCCCCCC
F: GCTGGGAGTCATGGAGCCG
559
IL-6 R: CCACACAGACAGCCACTCAC
F: AGGTTGTTTTCTGCCAGTGC
146
IL-8 R: ACTTCCAAGCTGGCCGTGGCTCTCTTGGCA
F: TGAATTCTCAGCCCTCTTCAA AAACTTCTC
295
TNF-a R: ATCTTCTCGAACCCCGAGTGA
F: CGGTTCAGCCACTGGAGCT
83
CXCL10 R: AGGAACCTCCAGTCTCAGCA
F: CAAAATTGGCTTGCAGGAAT
193
CXCL2 R: TGCCAGTGCTTGCAGAC
F: TCTTAACCATGGGCGATGC
157
CCL4 R: CGCCTGCTGCTTTTCTTACAC
F: CAGACTTGCTTGCTTCTTTTGG
126
PKR R: ATGATGGAAAGCGAACAAGG
F: TTCTCTGGGCTTTTCTTCCA
76
HBV-X R: CCGTCTGTGCCTTCTCATCTGC
F: ACCAATTTATGCCTACAGCCTCC
256
HBV S/P R: ATCCTGCTGCTATGCCTCATCTT
F: ACAGTGGGGGAAAGCCCTACGAA
314
doi:10.1371/journal.pone.0027931.t002
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iCycleriQ real-time PCR system (Bio-Rad, USA).
Flow cytometry
The cells were transfected with siRNA for 4 h. Intracellular
detection of Stat-1 activation was determined by flow cytometry.
Briefly, the cells were washed once before fixing in 0.4%
paraformaldehyde in the dark at 4uC for 30 min. Cells were then
washed twice in PBS before incubation with phycoerythrin (PE)-
labeled antibody (Ab) to p-Stat-1 (BD Pharmingen, USA).
Intracellular staining was performed in FACS buffer containing
0.01% saponin at 4uC for 1 h. Results were analyzed by FACS
Calibur
TM and CELL Quest
TM software.
Western blot analysis
HepG2.2.15 cells were lysed in lysing buffer [20 mM Tris–HCl,
150 mM NaCl, 1 mM Na3VO4, 1 mM ethylenediaminetetraacetic
acid (EDTA),1 mMethyleneglycoltetraaceticacid (EGTA),1 mM
phenylmethylsulfonyl fluoride (PMSF), 50 mM NaF and 1% NP-
40]. After SDS-PAGE, proteins were transferred to polyvinylidene
fluoride (PVDF) membranes and then incubated with the following
specific antibodies: mouse anti-human HBx mAb (Millipore, USA),
rabbit anti-human-PKR and anti-p-PKR mAb, rabbit anti-human-
eIF2-a and anti-p-eIF2-a mAb (Santa Cruz, CA, USA), or anti-
human-b-actin mAb (Cell Signaling Technology, New England
BioLabs Inc., USA) diluted in 1:1000 at 4uC. After washing with
Tris-buffered saline-Tween 20 (TBST) three times, the membranes
were incubated with horseradish peroxidase (HRP)-conjugated
secondantibody.ProteinbandswerevisualizedusingAnmobilon
TM
Western chemiluminescent HRP Substrate system (Millipore
Corporation. Billerica, Massachusetts, USA).
ELISA
The cells were treated as above. Supernatants were harvested
after 24 h or 48 h stimulation with siRNA (150 nM). The level of
IFNa was quantified using sandwich ELISA kits from R&D
Systems. The levels of HBsAg and HBeAg were detected by
ELISA kit from Rong Sheng (Shanghai, China).
Immunocytochemical staining
HepG2.2.15 cells were grown on glass cover slips in a 24-well
plate at a density of 5610
4 cells per well. Then, the cells were
transfected with HBx-siRNAs. After 48 h, the cells were fixed in 4%
paraformaldehyde for 10 min, and permeabilized with 0.2% Triton
X-100 for 30 min. Then cells were exposed to 3% H2O2 for 10 min
at 25uC and blocked in 5% bovine serum albumin (BSA) for
30 min. The cells were incubated with anti-core antigen (HBcAg)
antibody (Genetech company, Shanghai, China) at 4uC overnight,
washed, and incubated with appropriate biotin-conjugated second-
ary antibody for 10 min followed by incubation with streptavidin-
peroxidase for 10 min and 3,39-diaminobenzidine (DAB) detection.
The staining was visualized by light microscopy (Olympus).
Data analyses
Data are expressed as mean 6 SD for three or more
independent experiments. Statistical differences between any two
groups were determined by t-test. p-values ,0.05 were considered
statistically signficant.
Results
HBx-siRNAs inhibit HBV expression in HepG2.2.15 cells
In order to test the capability of HBx-siRNAs to inhibit HBV
replication in HepG2.2.15 cells, we delivered HBx-siRNAs into
HepG2.2.15 cells using Lipofectamine
TM 2000. Then HBx
expression was detected with quantitative RT-PCR at 24 h after
transfection with the four HBx-siRNAs. We found that treatment
with HBx-siRNAs resulted in decrease in HBx expression by
61.762.1%, 57.564.3%, 62.562.5%, and 72.663.1% (p,0.05)
respectively, in the total mRNA at a concentration of 100 nM,
compared with the LF-treated cells (Figure 1A, top). Western blot
analysis also showed a significant silencing effect of HBx-siRNAs
on HBx expression at protein level (Figure 1A, bottom).
Immunohistochemical staining for HBcAg in siRNA-treated
HepG2.2.15 cells allows us to directly observe the HBV clearance,
as the presence of cytoplasmic HBcAg is an indicator of active viral
replication. As shown in Figure 1B, cytoplasmic HBcAg staining in
HBx-siRNA-treated HepG2.2.15 cells decreased significantly at
48 h after transfection. Levels of HBsAg and HBeAg were also
inhibited significantly in a dose-dependent manner (Figure 1C and
1D). HBsAg secretion was reduced by 69.566.3% when siRNA4
was transfected at 150 nM. The scramble siRNA exhibited no
suppressive effect. These results demonstrated that HBx-siRNAs
not only silenced the expression of HBx gene, but also inhibited
the expression of HBcAg and secretion of HBsAg and HBeAg.
Innate immune responses induced by HBx-siRNAs in
HepG2.2.15 cells
The expression profile of several antiviral molecules was
investigated after HBx-siRNA transfection into HepG2.2.15.
Synthesis of mRNA for IFNa, IFNb, and interferon-stimulated
genes (ISG) were significantly induced as a consequence of HBx-
siRNA transfection, while scramble siRNA (100nM) has a weak
induction of IFN and ISGs (Figure 2). IFNa expression showed a
3.4-fold increase at 24 h after siRNA4 transfection at a
concentration of 150 nM when compared with mock-treated
cells. Moreover, induction of IFN responses is in a concentration-
dependent manner (Figure 2A).
Recent experiments have also indicated that interleukin (IL)-6
suppresses HBV replication in an HBV-producing cell line [25]. Our
results showed that the HBx-specific siRNAs induced mRNA
expression of tumor necrosis factor (TNF)-a a n dI L - 6u pt o3 . 6 - f o l d
relative to lipofectamine treatment in HepG2.2.15 cell lines (p,0.05)
(Figure 2B). The mRNA levels of IL-8 and inducible nitric oxide
synthase (iNOS) were also enhanced at 24 h post-transfection.
Scramble siRNA that was used as a negative control was not capable
of inducing expression of IL-8, IL-6, iNOS, and TNF-a in
HepG2.2.15 cells (Figure 2B). Similar results were also observed in
both HepG2 and HL-7702 cell lines (data not shown).
We further detected phosphorylation of Stat1, a molecule
downstream of the type I IFN signaling pathway. Flow cytometry
revealed a signficantly higher level of p-Stat1 expression in
HepG2.2.15 cells that had been transfected by HBx-siRNAs for
4 h (Figure 2C). In order to see if Stat1 phosphorylation is due to
IFN induction, we blocked the type I IFN pathway with a
neutralizing antibody against the IFN-a/b receptor. The results
showed that p-Stat1 activation was suppressed after IFN receptor
neutralization (Figure 2C, bottom). The expression of inflamma-
tory-related chemotactic factors, such as CXCL2, CCL4 and
CXCL10, did not change signficantly after HBx-siRNA transfec-
tion (Figure 2D). These results demonstrated that HBx-siRNAs
induced the expression of type I IFN and related genes as well as
inflammatory cytokines in HepG2.2.15 cells.
HBx-siRNAs promote the activation of PKR and its
downstream signal pathway
Several reports have demonstrated that siRNA can induce IFN
responses in immune and non-immune cells and that these
Activation of PKR on HBV Inhibition
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signature of viral infection [15,23,24,25]. PKR activation is found
to be involved in the innate immune responses induced by siRNA
[19]. To explore the possible mechanism of HBx-siRNA-mediated
IFN induction, the expression level of PKR was examined. RT-
PCR analysis demonstrated that transfection of HepG2.2.15 cells
with HBx-siRNA did increase the expression of PKR at the
mRNA level (Figure 3A). Western blot analysis demonstrated that
transfection with HBx-siRNA promoted the phosphorylation of
PKR, and that the PKR substrate eIF2-a was also phosphorylated
(Figure 3B). We further performed a longer kinetics over a few
hours (0, 4, 6, 8, 12 and 24 h) and found that HBx-siRNA
promoted the phosphorylation of PKR until 6 h and enhanced the
activation of eIF2-a until 12 h post-transfection (Figure 3C), while
the scramble siRNA showed a weak activation of PKR (Figure 3D).
These results demonstrated that PKR might be involved in the
immune responses induced by HBx-siRNA in HepG2.2.15 cells.
PKR is involved in the innate immune responses induced
by HBx-siRNAs in HepG2.2.15 cells
To find out if PKR is indeed responsible for the immunomod-
ulatory effects of HBx-siRNAs, we first treated HepG2.2.15 cells
with PKR specific inhibitor C16 and then transfected cells with
HBx-siRNA4. We found that the induction of IFN-a and IFN-b
mRNA as well as the expression of IFN-stimulated genes ISG15
and ISG56 were attenuated significantly after HBx-siRNA
transfection (Figure 4A and 4B). p-Stat1 activation was also
suppressed as assayed by flow cytometry (Figure 4C). In addition,
proinflammatory factors TNF-a and IL-6 were also decreased
when C16 was added (Figure 4D). We then cotransfected siRNA
targeting PKR (siPKR) and HBx-siRNA in HepG2.2.15 cells to
further determine the involvement of PKR in the innate immune
responses. As shown in Figure 4E, siPKR decreased PKR protein
level (top) and significantly attenuated the induction of IFN-a and
IFN-b (bottom).
Figure 1. HBx-siRNA inhibits hepatitis B virus (HBV) expression in HepG2.2.15 cells. (A) Scramble siRNA or HBx-siRNA (siRNA1, siRNA2,
siRNA3, siRNA4) (100 nM) was transfected into HepG2.2.15 cells using lipofectamine 2000 (LF). LF-treated group was used as a control. The cells were
harvested, and RNA was extracted at 24 h after transfection. Expression of HBx mRNA were detected by real-time PCR (top). The level of each sample
is expressed as the percentage of the RNA level in scramble siRNA-treated cells. The levels of HBx protein were detected by western blot at 48 h after
transfection (bottom). (B) HepG2.2.15 cells were transfected for 48 h, and then cells were fixed, immunostained for HBcAg and visualized under a
microscope. Representative fields from each cell group are shown (original magnification 6100). (C, D) The supernatants were harvested after 48 h,
and the dose-dependent reductions in HBsAg (C) and HBeAg (D) were detected with ELISA. Data showing the silencing effect are representative of
three independent experiments. Data are expressed as the mean 6 SD from at least three separate experiments. *p,0.05 versus the LF-treated
group.
doi:10.1371/journal.pone.0027931.g001
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length PKR plasmids followed by HBx-siRNA transfection. As
illustrated in Figure 5A, PKR was successfully over-expressed in
HepG2.2.15 cell line at the transcriptional level. We found that the
mRNA levels of IFN-a and IFN-b in PKR-overexpression cells
were increased more markedly when stimulated with HBx-siRNA
than that in control vector-transfected cells (Figure 5B, 5C).
Furthermore, HepG2.2.15 cells were transfected with a PKR
catalytically inactive vector (hPKR-K296R) [26]. As the PKR-
K296R plasmid contains the C-terminal Myc epitope and
polyhistidine tag (His-tag), we assayed 6His expression by FACS
to detect the PKR-K296R expression. The results showed that
PKR-K296R has been successfully expressed (Figure 5F, top). We
found that PKR-K296R overexpression could not further promote
type I IFN production induced by HBx-siRNA as full-length PKR
(wide type) did (Figure 5F, bottom). These results suggest that the
promotion of PKR in IFN induction mediated by HBx-siRNA is
dependent on the catalytic activity of PKR. In general, the results
above confirm that PKR activation indeed contributes to the
innate immune responses induced by HBx-siRNAs.
PKR activation contributes to HBV inhibition in
HepG2.2.15 cells
To determine if immune stimulation induced by HBx-siRNAs
contributes to the inhibition of HBV, HepG2.2.15 cells were
treated with C16 to inhibit PKR activity before HBx-siRNA
transfection. As shown in Figure 6, C16 strongly attenuated the
effects of HBx-siRNAs in HBV inhibition. Transfection of HBx-
siRNAs resulted in 63.2, 68.5, 69.6, and 65.8% suppression of
HBx gene expression respectively compared with the solvent
treatment group. Treatment with C16 significantly attenuated the
suppression of HBx expression (Figure 6A). The inhibition of HBV
DNA, HBsAg or HBcAg was also attenuated (Figure 6B–6D). We
further knocked down PKR expression in HepG2.2.15 cells by
siPKR, and found that siPKR also significantly attenuated the
HBx inhibition by HBx-siRNA (Figure 6E).
To further determine if the observed up-regulation of PKR
leads to a reduction in HBV apart from the specific inhibition of
HBV through RNAi pathway, we transfected HepG2.2.15 cells
with plasmid containing full-length PKR, and then assessed the
changes in HBV expression. As shown in Figure 5D and 5E, the
Figure 2. HBx-siRNA induced the expression of type I interferon (IFN) and inflammatory cytokines in HepG2.2.15 cells. (A)
HepG2.2.15 cells were transfected with HBx-siRNAs; 24 h later, the mRNA levels of IFN-a, IFN-b, ISG15 and ISG56 were measured by real-time PCR. The
mRNA level in each sample was expressed as a fold change of the RNA level in lipofectamine (LF)-treated cells. The levels of mRNA are presented
relative to mock control. (B) Cells were transfected with HBx-siRNAs for 24 h. Levels of TNF-a, IL-6, iNOS, and IL-8 mRNA were analyzed by real-time
PCR and presented relative to those of LF-treated cells. (C) HepG2.2.15 cells were incubated with phycoerythrin (PE)-labelled anti-p-Stat1 antibody
after HBx-siRNA transfection for 4 h, and were then analyzed by flow cytometry. p-Stat1 expression was also detected when IFN receptor was
neutralized. (D) Levels of CXCL2, CCL4, and CXCL10 mRNA were analyzed by real-time PCR and presented relative to those of LF-treated cells. Data are
expressed as the mean 6 SD from at least three separate experiments. *p,0.05 versus LF-treated group.
doi:10.1371/journal.pone.0027931.g002
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with over-expression of PKR. These results indicated that over-
expression of PKR further increased the inhibition of HBV
expression by HBx-siRNAs and that recognition and activation of
PKR were involved in and promoted the inhibition of HBV
expression by siRNA. In conclusion, our results suggested that
HBx-siRNAs-induced innate immune responses play important
roles in HBV inhibition and clearance in addition to the direct
RNA silencing by RNAi.
Discussion
This study and earlier studies have shown that RNAi can be
successfully used for HBV inhibition. In addition, we report that:
(1) HBx-siRNA can induce innate immune response associated
with the release of type I IFN and related cytokines in HepG2.2.15
cells; (2) this effect does boost silencing of specific targets; and (3)
these innate immune stimulatory effects of lipid-siRNA in
HepG2.2.15 cells are at least partly mediated by the cytoplasmic
kinase, PKR.
Studies have demonstrated that RNA can be recognized by
PRRs, including PKR, TLR3, TLR7, TLR8, RIG-I and MDA-5
[19,21,23,27,28]. PKR is an important cytoplasmic sensor of viral
infection that can be activated by dsRNA. During viral infection,
PKR can phosporylate eIF2-a and activate the NF-kB pathway
for regulation of cytokine expression and the inflammatory
response [19,20,21]. The RNA-binding sites of PKR contain
two dsRNA-binding motifs (dsRBMs) linked by 20 amino acids.
Previous studies have suggested that PKR required at least 30 bp
of dsRNA for efficient activation, whereas another study
demonstrated that as little as 17 bp of dsRNA could activate
PKR signal [29,30]. Recent studies have reported that siRNA
induces non-specific immunostimulatory effects in non-immune
cells, such as epidermal keratinocytes, breast cancer cell MCF-7,
glioma cell T98G, mouse embryo fibroblasts MEFs and renal cell
carcinoma [19,21,23,31]. Here, for the first time, we found the up-
regulation of type I IFN and related genes as well as inflammatory
cytokines, the increased expression of PKR, and the phosphory-
lation of eIF2-a in HepG2.2.15 cells after exposure to HBx-
siRNAs. Inhibition of PKR activity by PKR inhibitor C16 or
Figure 3. HBx-siRNA promoted the expression of PKR and the activation of PKR signaling pathway. (A) Real-time PCR was used to
analyze the mRNA expression of PKR after HBx-siRNAs treatment for 24 h. The mRNA level in each sample was expressed as fold change compared
with RNA level in LF-treated cells. Data are expressed as the mean 6 SD from at least three separate experiments. *p,0.05 versus LF-treated group.
(B) Western blot analysis of the activation of the protein kinase R (PKR) and PKR substrate, translation initiation factor 2 (eIF-2)a, from HepG2.2.15
cells. Cells were transfected with siRNA4 (150 nM) at different time points (0, 30, 60, 90, 120, and 180 min) using lipofectamine. The panel used an
antibody specific to whole PKR or eIF2-a that demonstrates equal loading of total protein. Histogram showed the relative expression of p-PKR or p-
eIF2-a after normalization to whole PKR or eIF2-a (right). (C) Western blot analysis of the activation of the PKR and eIF2-a by siRNA4 at different time
points (0, 4, 6, 8, 12, and 24 h). Histogram showed the relative expression of p-PKR or p-eIF2-a (bottom). (D) Western blot analysis of the activation of
the PKR by scramble siRNA at different time points (0, 4, 6, 8, 12, and 24 h). Histogram showed the relative expression of p-PKR (bottom).
doi:10.1371/journal.pone.0027931.g003
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e27931silencing of PKR expression by RNAi significantly attenuated
these effects, while PKR overexpression further promoted IFN
responses and HBV inhibition. Our results demonstrated that
HBx-siRNAs activated innate immune responses in hepatoma cells
in a PKR-dependent manner. We attribute this HBV inhibition to
the combination of RNAi and immune stimulation, which may
arise from the production of type I IFN and other antiviral genes.
In addition, we found that HBx-siRNAs transfection also increased
TLR3 expression significantly and promoted RIG-I expression
slightly in HepG2.2.15 cells (data not shown). We propose that
TLR3 and RIG-I recognition might also contribute to the
activation of innate immune responses induced by HBx-siRNAs,
which need to be further determined. It is well known that TLRs
can respond to RNA molecules and play crucial roles in the host
defense against viral infection. In plasmacytoid dendritic cells,
siRNA induces IFN-a secretion in a sequence-dependent manner
through TLR7 [28]. Here, in HepG2.2.15 cells, we observed that
HBx-siRNAs transfection neither stimulated TLR7 expression,
nor activated the TLR7 signaling pathway (data not shown), thus
suggesting that TLR7 is not involved in HBx-siRNA recognition
in HepG2.2.15 cells.
As a direct evidence of PKR activation, eIF2-a phosphorylation
is thought to inhibit translation of most cell and viral mRNAs [32].
However, some reports have found that it do not affect the overall
translation of the cell mRNAs [33]. In contrast, translation of some
mRNAs is enhanced after eIF2-a phosphorylation. For example,
activation of PKR can induce the expression of Fas and trigger
apoptosis through the FADD/caspase-8 death signaling pathway
Figure 4. Inhibition of protein kinase R (PKR) activity attenuated HBx-siRNA-induced innate immune responses. (A) HepG2.2.15 cells
were treated with or without PKR inhibitor C16, and then transfection experiments were performed for 24 h. Levels of IFN-a and IFN-b mRNA were
analyzed by real-time PCR and presented relative to mock transfection (left). The levels of IFN-a in supernatants were examined by ELISA (right). (B)
The experiment was performed as Fig. 4A. Levels of IFN-stimulated gene (ISG)15 and ISG56 mRNA were analyzed by real-time PCR and presented
relative to mock transfection. (C) p-Stat1 expression was detected by flow cytometry when siRNA was transfected for 4 h. (D) The experiment was
performed as Fig. 4A, mRNA levels of TNF-a and IL-6 were analyzed by quantitative real-time PCR and were presented relative to mock transfection.
(E) siPKR were transfected into cells, then PKR protein expression was assayed by Western Blot (top). siRNA4 and siRNA targeting PKR were
cotransfected into HepG2.2.15 cells for 24 h, then mRNA levels of IFN-a and IFN-b were analyzed and presented relative to mock transfection
(bottom). Data are expressed as the mean 6 SD from at least three separate experiments. *p,0.05 versus siRNA4-treated group.
doi:10.1371/journal.pone.0027931.g004
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e27931[34,35]. For type I IFN, it has been found that PKR activation
promotes the production of autocrine IFN, in addition to
inhibiting the translation of viral mRNAs through phosphorylation
of eIF2-a [36]. Indeed, we show in the present study that PKR
activation by HBx-siRNA increased production of IFN-a and
IFN-b both at mRNA and protein level (Figure 4A). The
mechanisms is probably that PKR activation transmits signals
not only to eIF2-a and the translational machinery but also to
variousfactorssuchasSTAT,interferonregulatoryfactor1 (IRF-1),
as well as engaging the NF-kB pathway.
Accumulating data have shown that HBV products inhibit type I
IFN production through suppressing TLR- or RIG-I-madiated
innate immune signal pathway [37,38,39]. Recent data suggest that
HBV-bearing supernatants,purifiedHBV virions,andrecombinant
HBsAg or HBeAg can suppress the innate immune response elicited
by TLR stimulation in hepatocytes and nonparenchymal liver cells,
leading to suppression of IRF-3 activation and down-regulation of
IFN-b production [38,40]. HBx, acting as an inhibitor of TLR-
triggeredinductionoftypeIIFNs,suppressesMxAexpressionatthe
promoterleveland inhibitscellularproteasomeactivities[39,41,42].
Our recent finding and other research show that HBV, particular
HBx, inhibits RIG-I activation and down-regulates production of
type I IFN [41,42,43]. Therefore, we concluded that the type I IFN
induction in response to HBx-siRNAs probablly derived from two
aspects: on one hand, HBx-siRNAs stimulate PKR activation and
then induce IFN-a or IFN-b production;on the other hand, HBx-
siRNAs relieve the inhibition of innate immune response mediated
by HBV.
The present study showed that HBx-siRNA-induced PKR
activation contributes to HBV inhibition and this dual function of
HBx-siRNAs in both inhibiting HBV replication and triggering
innate immunity in a PKR-dependent manner would be beneficial
for HBV clearance. In addition to type I IFN, levels of
inflammatory cytokines TNF-a, IL-6, and IL-8 were also increased
significantly upon PKR activation by HBx-siRNA (Figure 2B), we
believed that they contributes to the suppression of HBV
replication, as reported by others that inflammatory cytokines,
esp. IL-6, control HBV gene expression in HBV infection [25,44].
Future work will focus on in vivo immune modulation strategies of
these dual functional HBx-siRNAs available to inhibit HBV.
Figure 5. Protein kinase R (PKR) over-expression enhanced type I interferon (IFN) production and HBx-siRNA-mediated hepatitis B
virus (HBV) inhibition. HepG2.2.15 cells were transfected with 2 mg of full-length PKR plasmid or the control plasmid. 24 h later, the cells were
transfected with HBx-siRNA (150 nM). (A) Over-expression of PKR at the transcriptional level. (B, C) Levels of IFN-a and IFN-b were detected by real-
time PCR at 24 h. (D, E) mRNA expression levels for HBx and HBs/p were detected by real-time RT-PCR at 24 h. (F) HepG2.2.15 cells were transfected
with 1 mg of hPKR-K296R or the control plasmid. Then cells were collected and 6-His was assayed by FACS (top). When transfected with hPKR-K296R
for 24 h, the cells were transfected with HBx-siRNA4 (150 nM). Another 24 h later, levels of IFN-a and IFN-b were detected. The levels of all examined
parameters were expressed as percentages of the corresponding parameter in LF-treated control-vector transfected cells (bottom). Data are
expressed as the mean 6 SD from at least three independent experiments. *p,0.05 versus corresponding control-vector transfected cells.
doi:10.1371/journal.pone.0027931.g005
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e27931In conclusion, this study demonstrates that HepG2.2.15 cells
can recognize siRNA and develop non-specific innate immune
responses through intracellular kinase PKR and that the induction
of innate responses facilitates the effects of HBV inhibition. In
addition to HBV, other virus-related siRNAs, such as siRNA
targeting respiratory syncytial virus NS1 (siNS1) and siRNA
targeting human papillomavirus (HPV), are also reported to
induce innate immune responses by upregulating expression of
IFN-b and IFN-inducible genes [45,46]. Understanding and
controlling the activation of the immune response is an important
step toward using siRNA molecules therapeutically. The combi-
nation of RNAi and immune stimulation may be beneficial for
treatment of HBV and other infectious virus diseases, raising
concerns about clinical trials of systemically delivered siRNAs.
Author Contributions
Conceived and designed the experiments: CZ JZ ZT. Performed the
experiments: QH. Analyzed the data: QH CZ JZ ZT. Wrote the paper:
QH CZ ZT.
References
1. Seeger C, Mason WS (2000) Hepatitis B virus biology. Microbiol Mol Biol Rev
64: 51–68.
2. Hannon GJ (2002) RNA interference. Nature 418: 244–251.
3. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001)
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila
melanogaster embryo lysate. EMBO J 20: 6877–6888.
4. Konishi M, Wu CH, Wu GY (2003) Inhibition of HBV replication by siRNA in
a stable HBV-producing cell line. Hepatology 38: 842–850.
5. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, et al. (2003)
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:
639–644.
6. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, et al. (2005)
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus
replication. Hepatology 41: 1349–1356.
7. Shlomai A, Shaul Y (2003) Inhibition of hepatitis B virus expression and
replication by RNA interference. Hepatology 37: 764–770.
8. Sabbah A, Chang TH, Harnack R, Frohlich V,TominagaK, et al. (2009) Activation
of innate immune antiviral responses by Nod2. Nat Immunol 10: 1073–1080.
9. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, et al. (2010) RIG-I
detects viral genomic RNA during negative-strand RNA virus infection. Cell
140: 397–408.
10. Habjan M, Andersson I, Klingstrom J, Schumann M, Martin A, et al. (2008)
Processing of genome 59 termini as a strategy of negative-strand RNA viruses to
avoid RIG-I-dependent interferon induction. PLoS One 3: e2032.
11. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, et al. (2006) 59-Triphosphate
RNA is the ligand for RIG-I. Science 314: 994–997.
1 2 . K a t oH ,T a k e u c h iO ,M i k a m o - S a t o hE ,H i r a iR ,K a w a iT ,e ta l .( 2 0 0 8 )L e n g t h -
dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible
Figure 6. Inhibition of protein kinase R (PKR) activity attenuated HBx-siRNA-induced hepatitis B virus (HBV) inhibition. HepG2.2.15
cells were treated with or without C16, and then transfection experiments were performed at a concentration of 150 nM. Levels of HBx RNA mRNA
(A) and HBsAg proteins in supernatants (C) were examined as described previously. Levels were expressed as percentages of corresponding levels in
scramble siRNA-treated cells. HBV DNA in supernatants was detected by real-time PCR (B). Immunostaining for HBcAg were visualized under a
microscope (D). siRNA4 and siPKR were cotransfected into HepG2.2.15 cells, then levels of HBx mRNA were analyzed by quantitative real-time PCR
and presented relative to mock transfection (E). Data are expressed as the mean 6 SD from at least three independent experiments. *p,0.05 versus
corresponding solvent-treated group.
doi:10.1371/journal.pone.0027931.g006
Activation of PKR on HBV Inhibition
PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e27931gene-I and melanoma differentiation-associated gene 5. J Exp Med 205:
1601–1610.
13. Takahasi K, Yoneyama M, Nishihori T, Hirai R, Kumeta H, et al. (2008)
Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral
immune responses. Mol Cell 29: 428–440.
14. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006)
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA
viruses. Nature 441: 101–105.
15. Kariko K, Bhuyan P, Capodici J, Weissman D (2004) Small interfering RNAs
mediate sequence-independent gene suppression and induce immune activation
by signaling through toll-like receptor 3. J Immunol 172: 6545–6549.
16. Sioud M (2005) Induction of inflammatory cytokines and interferon responses by
double-stranded and single-stranded siRNAs is sequence-dependent and
requires endosomal localization. J Mol Biol 348: 1079–1090.
17. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. (2005) Sequence-
dependent stimulation of the mammalian innate immune response by synthetic
siRNA. Nat Biotechnol 23: 457–462.
18. Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, et al. (2009)
Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK
cell response through the TLR7. J Immunol 183: 6078–6086.
19. Zhang Z, Weinschenk T, Guo K, Schluesener HJ (2006) siRNA binding proteins
of microglial cells: PKR is an unanticipated ligand. J Cell Biochem 97:
1217–1229.
20. Nayak R, Pintel DJ (2007) Adeno-associated viruses can induce phosphorylation
of eIF2alpha via PKR activation, which can be overcome by helper adenovirus
type 5 virus-associated RNA. J Virol 81: 11908–11916.
21. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation
of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834–839.
22. Armstrong ME, Gantier M, Li L, Chung WY, McCann A, et al. (2008) Small
interfering RNAs induce macrophage migration inhibitory factor production
and proliferation in breast cancer cells via a double-stranded RNA-dependent
protein kinase-dependent mechanism. J Immunol 180: 7125–7133.
23. Gorina R, Santalucia T, Petegnief V, Ejarque-Ortiz A, Saura J, et al. (2009)
Astrocytes are very sensitive to develop innate immune responses to lipid-carried
short interfering RNA. Glia 57: 93–107.
24. Davis AM, Hagan KA, Matthews LA, Bajwa G, Gill MA, et al. (2008) Blockade
of virus infection by human CD4+ T cells via a cytokine relay network.
J Immunol 180: 6923–6932.
25. Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, et al. (2009) HBV replication
is significantly reduced by IL-6. J Biomed Sci 16: 41.
26. Saelens X, Kalai M, Vandenabeele P (2001) Translation inhibition in apoptosis:
caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol
Chem 276: 41620–41628.
27. Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, et al. (2009)
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic
vessel growth. Proc Natl Acad Sci U S A 106: 7137–7142.
28. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, et al.
(2005) Sequence-specific potent induction of IFN-alpha by short interfering
RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263–270.
29. Manche L, Green SR, Schmedt C, Mathews MB (1992) Interactions between
double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 12:
5238–5248.
30. Nanduri S, Carpick BW, Yang Y, Williams BR, Qin J (1998) Structure of the
double-stranded RNA-binding domain of the protein kinase PKR reveals the
molecular basis of its dsRNA-mediated activation. EMBO J 17: 5458–5465.
31. Armstrong ME, Gantier M, Li L, Chung WY, McCann A, et al. (2008) Small
interfering RNAs induce macrophage migration inhibitory factor production
and proliferation in breast cancer cells via a double-stranded RNA-dependent
protein kinase-dependent mechanism. J Immunol 180: 7125–7133.
32. Clemens MJ, Elia A (1997) The double-stranded RNA-dependent protein kinase
PKR: structure and function. J Interferon Cytokine Res 17: 503–524.
33. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, et al. (2006) Impact of
protein kinase PKR in cell biology: from antiviral to antiproliferative action.
Microbiol Mol Biol Rev 70: 1032–1060.
34. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, et al. (1998) Activation
of the dsRNA-dependent protein kinase, PKR, induces apoptosis through
FADD-mediated death signaling. EMBO J 17: 6888–6902.
35. Donze O, Dostie J, Sonenberg N (1999) Regulatable expression of the
interferon-induced double-stranded RNA dependent protein kinase PKR
induces apoptosis and fas receptor expression. Virology 256: 322–329.
36. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, et al. (2000)
Essential role for the dsRNA-dependent protein kinase PKR in innate immunity
to viral infection. Immunity 13: 129–141.
37. Yu S, Chen J, Wu M, Chen H, Kato N, et al. (2010) Hepatitis B virus
polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon
induction in human hepatocytes through interference with interferon regulatory
factor 3 activation and dampening of the interaction between TBK1/
IKKepsilon and DDX3. J Gen Virol 91: 2080–2090.
38. Xu Y, Hu Y, Shi B, Zhang X, Wang J, et al. (2009) HBsAg inhibits TLR9-
mediated activation and IFN-alpha production in plasmacytoid dendritic cells.
Mol Immunol 46: 2640–2646.
39. Jiang J, Tang H (2010) Mechanism of inhibiting type I interferon induction by
hepatitis B virus X protein. Protein Cell 1: 1106–1117.
40. Wu J, Meng Z, Jiang M, Pei R, Trippler M, et al. (2009) Hepatitis B virus
suppresses toll-like receptor-mediated innate immune responses in murine
parenchymal and nonparenchymal liver cells. Hepatology 49: 1132–1140.
41. Wang X, Li Y, Mao A, Li C, Tien P (2010) Hepatitis B virus X protein
suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting
the VISA-associated complex. Cell Mol Immunol 7: 341–348.
42. Wei C, Ni C, Song T, Liu Y, Yang X, et al. (2010) The hepatitis B virus X
protein disrupts innate immunity by downregulating mitochondrial antiviral
signaling protein. J Immunol 185: 1158–1168.
43. Han Q, Zhang C, Zhang J, Tian Z (2011) Reversal of hepatitis B virus-induced
immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid
inducible gene I-dependent manner. Hepatology 54: 1179–1189.
44. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, et al. (2009) Not
interferon, but interleukin-6 controls early gene expression in hepatitis B virus
infection. Hepatology 50: 1773–1782.
45. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, et al. (2005)
Inhibition of respiratory syncytial virus infection with intranasal siRNA
nanoparticles targeting the viral NS1 gene. Nat Med 11: 56–62.
46. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, et al. (2011) siRNA-
induced immunostimulation through TLR7 promotes antitumoral activity
against HPV-driven tumors in vivo. Immunol Cell Biol.
Activation of PKR on HBV Inhibition
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e27931